常压高氧联合血管内治疗急性缺血性卒中患者:一项随机对照临床试验
本研究为单中心、概念验证、评估者盲法、随机对照先导研究,纳入86例急性前循环大血管闭塞且具备血管内治疗指征的缺血性卒中患者,随机分为血管内治疗组与常压高氧联合血管内治疗组。结果显示联合组24-48小时梗死体积中位数显著小于单纯血管内治疗组(20.1 vs 37.7 mL,p<0.01),90天改良Rankin量表评分中位数联合组为2 vs 单纯组为3(校正值1.8,95%CI 1.3-4.2;p=0.038)。联合组症状性颅内出血、死亡及不良事件发生率数值上较低但差异无统计学意义。作者认为常压高氧联合血管内治疗似乎是安全可行的策略,需大型多中心随机临床试验进一步证实。
要点
- 常压高氧联合血管内治疗组24-48小时梗死体积中位数20.1 mL,显著小于单纯血管内治疗组的37.7 mL(p<0.01)。
- 90天改良Rankin量表评分中位数联合组为2 vs 单纯组为3(校正值1.8,95%CI 1.3-4.2;p=0.038)。
- 联合组症状性颅内出血7% vs 12%、死亡9% vs 16%、不良事件33% vs 42%,差异均无统计学意义。
核心结论
- 在急性缺血性卒中患者中,常压高氧联合血管内治疗与单纯血管内治疗相比,似乎能显著减少梗死体积、改善短期神经行为学评分并提升90天临床结局。
- 作者指出这些观察结果需通过大型多中心随机临床试验进一步证实。
研究设计与样本
- 单中心、概念验证、评估者盲法、随机对照先导研究。
- 筛查231例,随机入组86例,按1:1分为血管内治疗组(n=43)和常压高氧联合血管内治疗组(n=43)。
- 纳入急性前循环大血管闭塞且具备血管内治疗指征的缺血性卒中患者。
- 常压高氧联合血管内治疗组在血管再通前经面罩给予100%氧气(10L/min,持续4小时),血管内治疗组给予室内空气。
- 主要终点为随机化后24-48小时内MRI测量的梗死体积。
主要发现
- 常压高氧联合血管内治疗组随机化后24-48小时梗死体积中位数为20.1 mL,单纯血管内治疗组为37.7 mL,联合组显著小于单纯组(p<0.01)。
- 90天改良Rankin量表评分中位数联合组为2 vs 单纯组为3(校正值1.8,95%CI 1.3-4.2;p=0.038)。
- 与单纯血管内治疗组相比,联合组症状性颅内出血发生率7% vs 12%、死亡率9% vs 16%、不良事件发生率33% vs 42%,但差异无统计学意义。
关键数值与推荐
- 主要终点:随机化后24-48小时MRI梗死体积中位数联合组20.1 mL vs 单纯组37.7 mL(p<0.01)。
- 90天改良Rankin量表评分中位数联合组2 vs 单纯组3(校正值1.8,95%CI 1.3-4.2;p=0.038)。
- 症状性颅内出血发生率联合组7% vs 单纯组12%,差异无统计学意义。
- 死亡率联合组9% vs 单纯组16%,差异无统计学意义。
- 不良事件发生率联合组33% vs 单纯组42%,差异无统计学意义。
临床怎么用
- 作者认为常压高氧联合血管内治疗似乎是安全可行的治疗策略,可显著减少梗死体积、改善短期神经行为学测试评分并提升90天临床结局。
- 作者指出这些观察结果需大型多中心随机临床试验进一步证实。
局限性
- 作者指出这些观察结果需通过大型多中心随机临床试验进一步证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To investigate the safety and efficacy of normobaric hyperoxia (NBO) combined with endovascular treatment (EVT) in patients with acute ischemic stroke (AIS). METHODS: In this single-center, proof-of-concept, assessor-blinded, randomized, controlled pilot study, patients with AIS in the acute anterior circulation with large vessel occlusion who had an indication for EVT were randomly assigned to the EVT group or the NBO + EVT group. The NBO + EVT group was given 100% oxygen through a face mask initiated before vascular recanalization (10L/min for 4 hours), while the EVT group was given room air. The primary endpoint was infarct volume measured by MRI within 24-48 hours after randomization. RESULTS: A total of 231 patients were screened, and 86 patients were randomized into a ratio of 1:1 (EVT group, n = 43; NBO + EVT group, n = 43). The median infarction volume of the NBO + EVT group at 24-48 hours after randomization was significantly smaller than that of the EVT group (median 20.1 vs 37.7 mL, p < 0.01). The median mRS score at 90 days was 2 for the NBO + EVT group when compared with 3 for the EVT group (adjusted value 1.8, 95% CI 1.3-4.2; p = 0.038). Compared with the EVT group, the NBO + EVT group had a lower incidence of symptomatic intracranial hemorrhagic (7% vs 12%), mortality (9% vs 16%), and adverse events (33% vs 42%); however, such a difference was not statistically significant. DISCUSSION: NBO in combination with EVT seems to be a safe and feasible treatment strategy that could significantly reduce infarct volume, improve short-term neurobehavioral test score, and enhance clinical outcomes at 90 days when compared with EVT alone in patients with AIS. These observations need to be further confirmed by a large, multicenter, randomized clinical trial. CLINICAL TRIALS REGISTRATION: NCT03620370. CLASSIFICATION OF EVIDENCE: This pilot study provides Class I evidence that NBO combined with standard EVT decreases infarction volume in patients with acute anterior circulation stroke.
引用
- Li W, Qi Z, Ma Q, et al. Normobaric Hyperoxia Combined With Endovascular Treatment for Patients With Acute Ischemic Stroke: A Randomized Controlled Clinical Trial. Neurology. 2022. PMID: 35715198. doi:10.1212/WNL.0000000000200775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。